U.S. stock futures were lower this morning, with the Dow futures trading lower by around 25 points on Friday.
Shares of Ardelyx, Inc. (NASDAQ: ARDX) fell sharply in today’s pre-market trading after the company reported mixed fourth-quarter financial results.
Ardelyx reported quarterly losses of 12 cents per share which missed the analyst consensus estimate of losses of 10 cents. The company reported quarterly sales of $34.36 million, beating the analyst consensus estimate of $34.23 million, according to data from Benzinga Pro.
Ardelyx shares dipped 13.3% to $7.65 in pre-market trading.
Here are some big stocks recording losses in today’s pre-market trading session.
- Applied Optoelectronics, Inc. (NASDAQ: AAOI) shares dipped 38.2% to $12.58 in pre-market trading after reporting fourth-quarter results.
- indie Semiconductor, Inc. (NASDAQ: INDI) shares declined 15% to $5.86 in pre-market trading following weak quarterly sales.
- ModivCare Inc. (NASDAQ: MODV) shares tumbled 14.2% to $37.64 in pre-market trading after the company issued weak sales forecast for the first quarter.
- Booking Holdings Inc. (NASDAQ: BKNG) shares declined 9.1% to $3,545.61 in pre-market trading after the company reported fourth-quarter financial results.
- MercadoLibre, Inc. (NASDAQ: MELI) shares fell 8.1% to $1,671.42 in pre-market trading after the company reported fourth-quarter financial results.
- Copart, Inc. (NASDAQ: CPRT) shares declined 7.8% to $45.56 in pre-market trading after the company reported worse-than-expected second-quarter financial results.
- AVITA Medical, Inc. (NASDAQ: RCEL) shares fell 7.8% to $15.69 in pre-market trading following weak quarterly sales.
- Main Street Capital Corporation (NYSE: MAIN) declined 6% to $43.00 in pre-market trading following fourth-quarter financial results.
- Canaan Inc. (NASDAQ: CAN) shares fell 4.9% to $1.93 in pre-market trading. Canaan is expected to report fourth-quarter financial results on Feb. 27, 2024.
Now Read This: Investor Optimism Improves Further; S&P 500 Settles At Record High
Don’t forget to check out our premarket coverage here
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
